QHSS
16 May 2017
Panmure Gordon Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and raised its price target to 809p (from 737p).
rikid
16 May 2017
Re: Compensation ?... Based on past performance I am expecting a drop to £5.50 or below over the coming months. An excellent opportunity to buy back in.
Ambiorix1
16 May 2017
Compensation ?... BUT....The question is how is BTG going to compensate the fall of Lemtrade royalties ?This year's royalties were around 39 mil. To give an idea, this is 10 times as much as the revenu from Varithena sales. BTG will need something else to buy and this is not the good time is it. Nothing is cheap anymore.I expect a further fall in the SP from now on.Ambiorix.
d gaser
16 May 2017
Re: %Profits up 13%cash 155.5 m, prof 57.5m ... forgot this from my last post profit after tax was down ,plus I put mark up the wrong way round it should have read 71% not 17% sorry .BE HAPPYDAVE Earnings per shareThe calculation of the basic and diluted earnings per share is as follows:Year ended31 March Year ended31 March2017 2016Profit for the year (£m) 33.6 60.5
d gaser
16 May 2017
%Profits up 13%cash 155.5 m, prof 57.5m up The accounts appear to be good, with growth showing right across the board except and still holding good mark ups of near 17% how ever PneumRx® Coils are down on last years sales.The only thing that worries me here is, B.T.G don't mention the agreement regarding our snake bite product,in a press note last year it said ,B.T.G had agreed that Bioclon (which is a Mexican company) could start selling their own snake bite product into the US under licence from B.T.G in 2018, now that could hit our own sales of our own anti venom snake bit vaccine hard unless BTG have some way of mitigating this? I also note our current liabilities have increased to £165.5m,most of which are due soon. see section 8. Business Combination . Other than that, I can't find any thing that would course our price to fall 10% .How ever, they do say in the accounts they intend expanding further this year ,and if they have all ready found an acquisition ,then a lower share price would be better for B.T.G, if as usual they intend offering shares & cash,BE HAPPYDAVE Press Release BTG plc: Final Results Strong strategic progress in 2016/17 with double-digit growth in product sales London, UK, 16 May 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces its final results for the year ended 31 March 2017. Louise Makin, BTG's CEO, commented: "We have delivered strong double-digit product sales growth and generated significant cash flows, enabling us to invest in product innovation, clinical data, geographic expansion and acquisitions. We have a broad portfolio and a scalable platform, and there is momentum across the business. With the financial strength to continue our investment plans, we are well positioned to capture further value in the growing Interventional Medicine space and to deliver sustained business growth." 1. Certain financial measures in this press release, including adjusted operating profit, adjusted basic EPS and free cash flow, are not prepared in accordance with IFRS. All adjusted financial measures are explained on page 20, and are reconciled to the most directly comparable measure prepared in accordance with IFRS on pages 21 to 22.2. Constant Exchange Rate (CER) growth is computed by restating 2016/17 results using 2015/16 foreign exchange rates for the relevant period. •Interventional Medicine now the largest and fastest growing revenue contributor, delivering 15% organic CER growth (25% CER growth including Galil Medical)•Adjusted operating profit up 13% at CER in 2016/17•Strong financial position with £155.5m of cash at 31 March 2017•IFRS operating profit and IFRS EPS impacted by previously announced legal settlement (£28.0m)•Translation benefits from weaker sterling offset by hedging losses on forward contracts (£25.2m), impacting the year's Adjusted and IFRS EPS Operating highlights Interventional Medicine Oncology•Acquisition of Galil Medical, a leader in interventional oncology cryoablation technology•Liver cancer treatment DC Bead LUMI™, the first and only visible chemoembolising bead, approved in the EU and Canada•Availability of TheraSphere®, the radiation treatment for liver cancer, expanded in Asia; new dosimetry software launched•Collaboration with the Society of Interventional Oncology (SIO) to test locoregional therapies alongside immuno-oncology agents Vascular•Enrolment completed into OPTALYSE and ACCESS PTS studies of EKOS®, the blood clot treatment device•Steady increase in u
Mike Land
16 May 2017
Share fall Clearly something has moved the market - a leak of the results?
shugg1e
16 May 2017
Re: sell the news down another 20p from 1st post70p down
shugg1e
16 May 2017
sell the news Results OK but had a very good run so i guess it was already priced in shorters back in force todayI would wait for a better entry level.
pauloverdi
16 May 2017
Results !! Comments please Any comments on the results ??Paulo
up protherics
16 May 2017
Thanks for the repliies Lets hope Varithena is taking off
dave297
15 May 2017
Re: Results Following thectrading update we know that the results will be strong.Our SP is more likely to be influenced by the confidence implied by the outlook statement .Any hint of growth in sales of Varithena would be well received as unexpected.
Mike Land
15 May 2017
Re: Results Quite usual for a share that has gone up strongly pre results to dip after announcement but usually this is a short term movement so just hold on ........
up protherics
15 May 2017
Results I would be interested in any ones view on the pending results.INMO we are going to need exceptional results to either hold or move forward from this level.My concern is that they are going to announce a book build when they release the results.
seadoc
04 May 2017
Re: last quarter lemtrada sales up 79% t... Got this one wrong,Doffing hat to all holders,Seadoc
Katonga
26 Apr 2017
Is somethimg in the Air High volume again to-day--anyone any thoughts?
